The invention described herein relates generally to the use of human chorionic gonadotropin (hCG) or a subunit or variant thereof, in neurodevelopmental disorders. In particular, the present invention relates to the use of hCG and related compounds as described herein for treating or reducing the likelihood of cerebral palsy and its co-morbidities in a patient or subject including a neonate, an infant or a child.